2,551 Shares in Abbott Laboratories (NYSE:ABT) Bought by Hirtle Callaghan & Co LLC

Hirtle Callaghan & Co LLC acquired a new stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,551 shares of the healthcare product maker's stock, valued at approximately $289,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Cape Investment Advisory Inc. lifted its stake in Abbott Laboratories by 6.6% during the fourth quarter. Cape Investment Advisory Inc. now owns 1,236 shares of the healthcare product maker's stock worth $140,000 after purchasing an additional 76 shares during the last quarter. Cyrus J. Lawrence LLC boosted its stake in Abbott Laboratories by 9.0% in the fourth quarter. Cyrus J. Lawrence LLC now owns 954 shares of the healthcare product maker's stock worth $107,000 after buying an additional 79 shares in the last quarter. LMG Wealth Partners LLC raised its stake in shares of Abbott Laboratories by 3.8% during the fourth quarter. LMG Wealth Partners LLC now owns 2,161 shares of the healthcare product maker's stock worth $244,000 after acquiring an additional 80 shares in the last quarter. Jacobson & Schmitt Advisors LLC boosted its stake in shares of Abbott Laboratories by 2.9% in the 4th quarter. Jacobson & Schmitt Advisors LLC now owns 2,827 shares of the healthcare product maker's stock valued at $320,000 after purchasing an additional 80 shares in the last quarter. Finally, Glass Wealth Management Co LLC raised its position in Abbott Laboratories by 3.2% in the 4th quarter. Glass Wealth Management Co LLC now owns 2,640 shares of the healthcare product maker's stock worth $299,000 after purchasing an additional 81 shares during the period. Hedge funds and other institutional investors own 75.18% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other Abbott Laboratories news, SVP Eric Shroff sold 562 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total value of $77,651.54. Following the transaction, the senior vice president now owns 31,970 shares of the company's stock, valued at approximately $4,417,294.90. This represents a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the business's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $128.50, for a total value of $3,054,573.50. Following the sale, the executive vice president now owns 125,697 shares of the company's stock, valued at approximately $16,152,064.50. This represents a 15.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 116,449 shares of company stock valued at $15,463,316. 0.46% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of recent research reports. Citigroup raised their price objective on Abbott Laboratories from $135.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $135.00 price target on shares of Abbott Laboratories in a research note on Tuesday, January 21st. UBS Group increased their price objective on Abbott Laboratories from $146.00 to $148.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. Argus raised shares of Abbott Laboratories to a "strong-buy" rating in a research note on Tuesday, January 28th. Finally, Wells Fargo & Company increased their price target on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an "overweight" rating in a research report on Thursday, January 23rd. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $137.94.

Abbott Laboratories Stock Up 3.1 %

ABT traded up $3.88 during midday trading on Thursday, reaching $130.49. The company's stock had a trading volume of 3,571,824 shares, compared to its average volume of 6,796,225. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $226.31 billion, a price-to-earnings ratio of 17.06, a PEG ratio of 2.52 and a beta of 0.70. The stock's 50-day moving average is $129.35 and its 200-day moving average is $120.16. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, meeting analysts' consensus estimates of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The firm had revenue of $10.97 billion for the quarter, compared to analysts' expectations of $11.03 billion. During the same quarter in the prior year, the company posted $1.19 earnings per share. The business's revenue for the quarter was up 7.2% on a year-over-year basis. As a group, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $0.59 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 annualized dividend and a yield of 1.81%. Abbott Laboratories's payout ratio is 30.85%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.